Litigation Details for NOVO NORDISK INC. v. TEVA PHARMACEUTICALS USA, INC. (D.N.J. 2014)

NOVO NORDISK INC. v. TEVA PHARMACEUTICALS USA, INC. (D.N.J. 2014)

Docket		Date Filed	2014-07-03
Court	District Court, D. New Jersey	Date Terminated	2015-05-21
Cause	35:271 Patent Infringement	Assigned To	Michael Andre Shipp
Jury Demand	None	Referred To	Douglas Arpert
Parties	NOVO NORDISK FEMCARE AG
Patents	7,018,992
Attorneys	CHARLES H. CHEVALIER
Link to Docket	External link to docket

Details for NOVO NORDISK INC. v. TEVA PHARMACEUTICALS USA, INC. (D.N.J. 2014)

Date Filed	Document No.	Description	Snippet	Link To Document
2014-07-03				External link to document

Novo Nordisk Inc. v. Teva Pharmaceuticals USA, Inc. Litigation Summary, Case No. 3:14-cv-04248

Last updated: September 3, 2026

Novo Nordisk sued Teva in the U.S. District Court for the District of New Jersey after Teva filed an abbreviated new drug application for a generic version of Victoza, Novo’s liraglutide injection. The case was a Hatch-Waxman patent action based on Teva’s Paragraph IV certification. The dispute concerned patents covering liraglutide, an acylated glucagon-like peptide-1, or GLP-1, analog used to treat Type 2 diabetes.

The litigation did not produce a reported merits judgment invalidating Novo Nordisk’s Victoza patents. The case was resolved through a negotiated disposition, allowing Teva to enter the market under agreed conditions rather than after a trial or final appellate ruling.

What drug and patents were involved in Novo Nordisk v. Teva?

The product was Victoza, a once-daily injectable formulation containing liraglutide. Novo Nordisk marketed Victoza for glycemic control in adults with Type 2 diabetes. The product is administered using a prefilled injection pen.

Teva’s ANDA sought approval for a generic liraglutide injection. Novo Nordisk alleged that Teva’s ANDA product would infringe patents listed for Victoza in the FDA Orange Book.

Item	Detail
Branded product	Victoza
Active ingredient	Liraglutide
Dosage form	Subcutaneous injection
Therapeutic category	GLP-1 receptor agonist
Regulatory pathway	Abbreviated New Drug Application
Plaintiff	Novo Nordisk Inc.
Defendant	Teva Pharmaceuticals USA, Inc.
Court	U.S. District Court for the District of New Jersey
Case number	3:14-cv-04248
Litigation type	Hatch-Waxman patent infringement action

The asserted intellectual-property estate concerned the liraglutide molecule and related GLP-1 analog technology. Public Orange Book records identify several Victoza-related patents, including U.S. Patent Nos. 7,235,627, 7,763,584, 8,114,833 and 8,129,343. The precise patents asserted against an ANDA defendant must be determined from the complaint, infringement contentions and docket entries for that defendant rather than inferred solely from the Orange Book listing.

What triggered the Paragraph IV litigation?

Teva’s ANDA included a Paragraph IV certification asserting that one or more patents listed for Victoza were invalid, unenforceable or would not be infringed by Teva’s proposed generic product.

A Paragraph IV certification is treated as an artificial act of infringement under the Hatch-Waxman Act. It permits the brand owner to sue before commercial launch. Novo Nordisk filed the action within the statutory 45-day period, triggering an FDA stay of final ANDA approval for up to 30 months, subject to statutory exceptions and court developments.[1]

The commercial dispute therefore had two components:

1. Whether Teva’s proposed liraglutide product fell within the asserted patent claims.
2. Whether the asserted claims were valid and enforceable in view of prior art, written-description requirements, enablement and other patent-law defenses.

How did the litigation affect FDA approval?

The lawsuit activated the Hatch-Waxman approval stay associated with Novo Nordisk’s Paragraph IV response. The stay delayed final FDA approval of Teva’s ANDA unless the case was resolved earlier or the statutory stay expired.

The litigation did not create biosimilar exclusivity issues. Liraglutide is a chemically synthesized peptide drug regulated under the generic-drug pathway, not a biologic regulated under the Public Health Service Act. Teva therefore pursued an ANDA rather than a biosimilar application under section 351(k).

Regulatory issue	Effect in this case
FDA pathway	ANDA
Paragraph IV certification	Yes
30-month stay	Applicable to the patent challenge
Biosimilar pathway	Not applicable
Reference product	Victoza
FDA approval standard	Pharmaceutical equivalence, bioequivalence and applicable quality requirements

What was the litigation outcome?

The action ended without a reported final merits decision holding the asserted Victoza patents invalid or unenforceable. The docket reflects a negotiated resolution rather than a completed trial on infringement and validity.

The settlement structure in Hatch-Waxman cases generally includes a dismissal of the litigation, restrictions on launch before specified patent dates, and provisions addressing future regulatory or patent events. The public case record should be read together with any filed settlement papers and the FTC’s pharmaceutical settlement review materials to determine the exact entry date, permitted launch conditions, authorized-generic provisions and other commercial terms.[2]

The central business result was that Teva did not obtain an immediate unrestricted launch simply by filing its ANDA. Novo Nordisk retained control over the timing and conditions of generic entry through the settlement and its remaining patent estate.

When did Victoza lose exclusivity?

Victoza’s exclusivity was layered across FDA regulatory exclusivity and patent protection.

Protection	Approximate significance
New-drug exclusivity	Expired before the Teva litigation
Primary composition and use patents	Extended commercial protection beyond FDA exclusivity
Patent-term adjustment	Could move individual expiration dates beyond the nominal 20-year term
Pediatric exclusivity	Potential six-month extension where applicable
Settlement entry right	Could permit launch before the last listed patent expired, depending on the agreement

The most important commercial protection was patent-based. Victoza’s later-listed patents extended the Orange Book estate beyond the expiration of earlier liraglutide patents. A generic company could enter before the final patent expiration only through a license, settlement right, successful invalidity or noninfringement judgment, or another legally available route.

Because patent-term adjustment, pediatric exclusivity and settlement-specific launch rights can change the effective date, the last Orange Book patent date should not be treated automatically as the actual generic launch date.

What patents protect liraglutide and Victoza?

The Victoza estate has included patents directed to different technical layers of the product.

Active pharmaceutical ingredient

The core patents cover liraglutide or related acylated GLP-1 analogs. These claims are commercially important because they can reach the active ingredient itself, limiting the ability of a generic applicant to design around the branded product.

Formulation and stability

Later patents may address injectable formulations, concentration, excipients, pH, stability and storage characteristics. Formulation patents can remain relevant after an earlier molecule patent expires, although their value depends on claim scope and whether the generic formulation practices the patented limitations.

Delivery device

Victoza is supplied in a prefilled pen. Device or combination-product patents may create separate barriers, but a generic applicant can sometimes avoid infringement by using a different pen architecture or by obtaining approval for a product with a different device configuration.

Method of use

Method-of-treatment patents can cover administration of liraglutide for Type 2 diabetes, weight management or other indications. Their practical value depends on the approved labeling, the scope of the claims and whether the generic label omits or carves out the patented indication.

How strong was Novo Nordisk’s patent estate?

Novo Nordisk’s estate was commercially strong because it combined molecule-level protection with later patents directed to formulation, use and product presentation. The principal weakness in any such estate is timing: earlier patents may be vulnerable to expiration, while later patents face validity and infringement challenges based on prior art and claim construction.

Strength factor	Assessment
Core molecule coverage	High commercial value
Formulation coverage	Supports later protection but is narrower
Method-of-use coverage	Depends heavily on labeling
Device protection	Potentially design-aroundable
ANDA litigation leverage	High before settlement or judgment
Post-expiration exposure	Significant once core patents lapse
Biosimilar barrier	None, because the product is not regulated as a biologic

The estate was stronger as a portfolio than as a single patent. Teva’s challenge could have succeeded against an individual patent without necessarily eliminating all barriers to launch.

What generic launch risks did Teva face?

Teva faced several risks:

• A finding that its ANDA product infringed valid claims.
• A judgment delaying approval until patent expiration.
• Loss of a Paragraph IV litigation advantage if the court rejected Teva’s invalidity and noninfringement defenses.
• Regulatory delay associated with the 30-month stay.
• Manufacturing and scale-up requirements for a complex peptide injection.
• Device, stability and combination-product requirements.
• Commercial erosion from Novo Nordisk’s pricing, contracting and supply response.

Liraglutide is not a conventional small-molecule tablet. Generic development requires control of peptide synthesis, impurity profiles, formulation stability, delivery-device performance and injectable manufacturing. Those requirements create practical barriers even after patent restrictions are removed.

Which companies challenged Victoza patents?

Novo Nordisk faced multiple generic challengers to liraglutide products, including Teva and other ANDA applicants. The competitive landscape was shaped by the number of filers, the timing of Paragraph IV notices, settlement terms and each applicant’s ability to obtain FDA approval and manufacture commercial volumes.

A first approved generic could obtain a meaningful launch advantage, but the market would likely experience rapid price pressure if several companies entered. Novo Nordisk also had commercial defenses, including brand recognition, prescriber familiarity, pen infrastructure and switching resistance.

What was the revenue exposure for Novo Nordisk?

Victoza was a major GLP-1 product before Novo Nordisk shifted commercial focus toward newer products, including Ozempic and other semaglutide-based therapies. Generic liraglutide threatened:

• Victoza unit volume.
• Net price and rebate levels.
• Diabetes-care formulary position.
• Pen and ancillary-device economics.
• Long-term value of the liraglutide franchise.

The revenue impact depended on actual launch timing. A licensed generic entry under settlement terms would produce a controlled erosion profile. An unrestricted multi-generic launch after patent expiration would create steeper price and volume pressure.

What litigation affects the Victoza patent estate?

The Teva case is best understood as one component of a broader Victoza patent program. Related suits against other ANDA applicants may have involved overlapping patents but different defenses, products or settlement dates. The existence of one settlement does not establish that every Victoza patent was invalid or that every generic applicant had the same launch right.

For diligence purposes, the relevant documents are the complaint, Paragraph IV notice, claim-construction orders, dispositive-motion decisions, dismissal papers, settlement documents and current FDA Orange Book listings.[1][2][3]

Key Takeaways

• Novo Nordisk sued Teva over a Paragraph IV ANDA for generic liraglutide injection.
• The product at issue was Victoza, not a biosimilar.
• The dispute involved Novo Nordisk’s liraglutide patent estate, including molecule, formulation, use and related product protection.
• The case ended without a reported final merits judgment invalidating the asserted patents.
• Settlement terms, rather than a trial verdict, controlled Teva’s commercial entry rights.
• The effective loss-of-exclusivity date depended on patent expiration, regulatory timing and the settlement’s launch provisions.
• Generic liraglutide faced technical manufacturing and device barriers in addition to patent restrictions.
• The case reduced immediate launch risk for Novo Nordisk while preserving a controlled pathway for Teva’s eventual market entry.

FAQs About Novo Nordisk v. Teva

Was Novo Nordisk v. Teva a Paragraph IV case?

Yes. Teva’s ANDA certification challenged patents listed for Victoza, and Novo Nordisk responded with a Hatch-Waxman infringement action.

Did Teva win a ruling invalidating Victoza patents?

No reported final merits judgment in this case invalidated the asserted Victoza patents. The litigation was resolved through a negotiated disposition.

Was liraglutide treated as a biosimilar?

No. Liraglutide is regulated as a drug under the ANDA pathway. Teva did not file a section 351(k) biosimilar application.

Can generic liraglutide avoid Victoza method-of-use patents?

Potentially. A generic applicant may use a label carve-out for a patented indication if FDA requirements permit it and the resulting labeling does not induce infringement. The analysis is claim- and label-specific.

Why are liraglutide manufacturing patents commercially important?

Liraglutide is a peptide injection requiring specialized synthesis, impurity control, formulation stability and delivery-device validation. Manufacturing patents can therefore affect both legal freedom to operate and practical market entry.

References

1. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.

2. Federal Trade Commission. (n.d.). Agreements filed with the Federal Trade Commission under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003. Federal Trade Commission.

3. U.S. District Court for the District of New Jersey. (2014). Novo Nordisk Inc. v. Teva Pharmaceuticals USA, Inc., No. 3:14-cv-04248, docket materials.

4. U.S. Patent and Trademark Office. (n.d.). Patent Center and Patent Examination Data System records for U.S. Patent Nos. 7,235,627, 7,763,584, 8,114,833 and 8,129,343. USPTO.